“…In the prostaglandin (PG) and prostaglandin analogs (PGs), the inactivation of PGs is mainly realized by enzyme oxidation of the 15α-OH to the 15-keto group via the 15-PGDH pathway. To slow down (retard) the 15α-OH oxidation, some structural modifications have been done: the introduction of a 15-OH,15-methyl group [1], like in arbaprostil [2], prostalene [3], tioprostanide [4], etc., a 16-OH, 16-methyl group at C 16 carbon atom, like in mexiprostil [5], two methyl groups at C 16 , like in nocloprost [6], gemeprost [7,8], cyclopentyl and cyclohexyl scafolds for a few prostacyclin and carbacyclin type compounds, like: ataprost [9,10], CH-5084 [11], SC-43350 [12] for the first, and taprostene [13], U-68215 [14], RS-93427 [15] for the second. Some prostaglandins substituted at the C 16 carbon atom with cycloalkyl, aryl, heterocyclyl [16], furyl [17], methylene-2-(2-thiophene) [18] or C 15 with 2-indanyl [19], aryl or heteroaryl scafolds [20] are claimed in patents.…”